In concordance with these findings, on the molecular level, the combination treatment resulted in enhanced cleavage of caspases 8, 9 and 3 as well as PARP in U251 and LN229 glioblastoma cells (Figure 4D and 4E). The gene discussed is CASP8; the disease is glioblastoma.